Roche building bispecific franchise outside oncology with Vabysmo approval
Ophthalmic bispecific Vabysmo reaches crowded AMD, DME market with blockbuster potential
Roche adds a second non-oncology bispecific with blockbuster potential to its product portfolio with the approval of Vabysmo, further proof that bispecific antibodies are set to make an impact on drug development and commercial markets that extends beyond cancer.
Vabysmo faricimab-svoa is the first bispecific antibody approved for an ophthalmic indication, receiving FDA approval Friday for both age-related macular degeneration (wet AMD) and diabetic macular edema. ...